IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry
Gao, Run-lin1,2; Xu, Bo1,2; Lu, Shu-zheng3; Chen, Ji-lin1,2; Han, Ya-ling; Chen, Jun-zhu4; Gai, Lu-yue; Ge, Jun-bo5; Wang, Wei-min6; Du, Zhi-min; Huo, Yong7; Wang, Le-feng8; Gao, Wei9; Chen, Ji-yan10; He, Ben11; Jia, Guo-liang; Yang, Zhi-jian; Cao, Ke-jiang12; Li, Wei-min13; Shen, Wei-feng14; Wan, Zheng15; Huang, De-jia16; Zhu, Guo-ying17; CCSR Investigators
关键词registry drug-eluting stent Sirolimus-eluting stent
刊名INTERNATIONAL JOURNAL OF CARDIOLOGY
2008-04-25
DOI10.1016/j.ijcard.2007.02.031
125期:3页:339-346
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Cardiac & Cardiovascular Systems
研究领域[WOS]Cardiovascular System & Cardiology
关键词[WOS]RANDOMIZED CONTROLLED-TRIAL ; NATIVE CORONARY-ARTERIES ; BARE-METAL ; IMPLANTATION ; PACLITAXEL ; RESTENOSIS ; THROMBOSIS ; LESIONS ; REVASCULARIZATION ; PREDICTORS
英文摘要

Objective: This post-marketing surveillance registry is aimed at determining the safety and reliability of the CYPHER Select Sirolimus-eluting stent (SES) in routine clinical practice.

Background: Little information and angiographic follow-up data in large-scale "real world" registry is available for the CYPHER Select SES, an advanced-generation SES.

Methods: This was a prospective multicenter (20 centers) registry. 1189 consecutive patients who received at least 1 CYPHER Select SES during daily clinical practice were enrolled. Patients who underwent emergency stenting for acute myocardial infarction were excluded.

Results: The procedure′s success rate was 98.3% for CYPHER Select SES implantation, and follow-up rates were 98% with 100% data auditing. Target lesion revascularization (TLR) at 12 months occurred in 60 (5.14%) cases, cardiac death in 13 cases (1.11%), Q wave myocardial infarction (MI) in 5 cases (0.43%), non-Q-MI in 9 cases (0.77%), target vessel revascularization (TVR) in 67 cases (5.74%), and MACE defined as cardiac death, nonfatal MI and TLR in 76 cases (6.51%). MACE-free survival rate at 12 months was 93.7%. Angiographic follow-up at 9 months was performed in 418 (68.3%) lesions treated by CYPHER Select SES. The binary restenosis rate was 4.8% in-stent and 9.6% in-segment. Subgroup analysis showed diabetes, bifurcation lesion and combined use of different stents were independent risk factors of cumulative MACE. In-segment MLD <= 2.25 mm at post-procedure and ostial lesion was independent predictors of in-segment restenosis.

Conclusions: In this registry, the MACE, TLR, angiographic late loss and binary restenosis rates of CYPHER Select SES were similar to those reported in SES randomized trials and "real world" registries. The safety and efficacy of CYPHER Select SES shown in this registry are consistent with those seen in SES studies. (c) 2007 Elsevier Ireland Ltd. All rights reserved.

语种英语
WOS记录号WOS:000255677100008
引用统计
被引频次:13[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/64583
专题北京大学第二临床医学院
北京大学临床肿瘤学院_肿瘤放疗科
作者单位1.Peking Univ, Hosp 1, Beijing, Peoples R China
2.Beijing Red Cross Chaoyang Hosp, Beijing, Peoples R China
3.Peking Univ, Hosp 3, Beijing, Peoples R China
4.Shanghai Renji Hosp, Shanghai, Peoples R China
5.Jiangsu Prov Peoples Hosp, Jiangsu, Peoples R China
6.Haerbin Univ Med Sci, Affiliated Hosp 1, Harbin, Peoples R China
7.Shanghai Ruijin Hosp, Shanghai, Peoples R China
8.Tianjin Univ Med Sci, Gen Hosp, Tianjin, Peoples R China
9.Sichuan Univ, Hosp 1, Chengdu, Peoples R China
10.Wu Han Asian Heart Hosp, Wuhan, Peoples R China
11.Beijing An Zhen Hosp, Beijing, Peoples R China
12.Fudan Univ, Shanghai Zhongshan Hosp, Shanghai, Peoples R China
13.Peking Univ, Peoples Hosp, Beijing, Peoples R China
14.Chinese Acad Med Sci, Peking Union Med Coll, Cardivasc Inst, Beijing 100037, Peoples R China
15.Chinese Acad Med Sci, Peking Union Med Coll, Fu Wai Hosp, Beijing 100037, Peoples R China
16.Zhejiang Univ, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
17.Guangdong Prov Peoples Hosp, Guangzhou, Guangdong, Peoples R China
推荐引用方式
GB/T 7714
Gao, Run-lin,Xu, Bo,Lu, Shu-zheng,et al. Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry[J]. INTERNATIONAL JOURNAL OF CARDIOLOGY,2008,125(3):339-346.
APA Gao, Run-lin.,Xu, Bo.,Lu, Shu-zheng.,Chen, Ji-lin.,Han, Ya-ling.,...&CCSR Investigators.(2008).Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry.INTERNATIONAL JOURNAL OF CARDIOLOGY,125(3),339-346.
MLA Gao, Run-lin,et al."Safety and efficacy of the CYPHER Select Sirolimus-eluting stent in the "real world" - Clinical and angiographic results from the China CYPHER select registry".INTERNATIONAL JOURNAL OF CARDIOLOGY 125.3(2008):339-346.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Gao, Run-lin]的文章
[Xu, Bo]的文章
[Lu, Shu-zheng]的文章
百度学术
百度学术中相似的文章
[Gao, Run-lin]的文章
[Xu, Bo]的文章
[Lu, Shu-zheng]的文章
必应学术
必应学术中相似的文章
[Gao, Run-lin]的文章
[Xu, Bo]的文章
[Lu, Shu-zheng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。